[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354600-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354600-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","first-in-class-immuno-oncology-drug-apg157ds-repolarizes-innate-immune-cells-and-induces-durable-remission-in-a-syngeneic-glioblastoma-model","First-in-Class Immuno-Oncology Drug APG157DS Repolarizes Innate Immune Cells and Induces Durable Remission in a Syngeneic Glioblastoma Model","","APG157DS is a multi-component investigational immuno-oncology drug under active cancer trials, with reported efficacy in head and neck cancer. In a syngeneic glioblastoma mouse model, long-term APG157DS treatment achieved durable tumor remission in 50% of mice, whereas vehicle-treated mice reached humane endpoints by 42 days. The drug selectively repolarized tumor-associated macrophages from an Arg1high/iNOSlow immunosuppressive state to an Arg1low/iNOShigh tumoricidal phenotype, increasing intratumoral recruitment of NKp46+ natural killer cells and CD8+ cytotoxic T cells. APG157DS also suppressed VEGF and HIF-1α and showed selective immune targeting without off-target macrophage activation in peripheral tissues. These results support further clinical development for GBM and other immune-evasive cancers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/first-in-class-immuno-oncology-drug-apg157ds-repolarizes-innate-immune-cells-and-induces-durable-remission-in-a-syngeneic-glioblastoma-model/354600/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/first-in-class-immuno-oncology-drug-apg157ds-repolarizes-innate-immune-cells-and-induces-durable-remission-in-a-syngeneic-glioblastoma-model/354600.png","ImageObject",300,407,{"name":42,"@type":43},"PakDamar76","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What effect did long-term APG157DS treatment have in the syngeneic glioblastoma model?","Question",{"text":63,"@type":64},"Long-term APG157DS treatment produced durable tumor remission in 50% of mice, while all vehicle-treated mice reached humane endpoints within 42 days.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does APG157DS mechanistically change tumor-associated macrophages?",{"text":68,"@type":64},"APG157DS selectively repolarizes tumor-associated macrophages from an Arg1high/iNOSlow immunosuppressive phenotype to a tumoricidal Arg1low/iNOShigh state.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence indicates APG157DS has selective immune targeting?",{"text":72,"@type":64},"APG157DS did not elicit off-target macrophage activation in peripheral tissues such as the spleen, indicating selective immune targeting.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354600,1790176592,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article  \nFirst-in-Class Immuno-Oncology Drug APG157DS Repolarizes Innate Immune Cells and Induces Durable Remission in a Syngeneic Glioblastoma Model  \nShubhasmita Mohapatra 1, Adrian Guerrero 2, Neha Rahman 3, Stefan Markovic 3, Lauren O’Donnell 3, Youssef Zaim Wadghiri 3, Khondoker Takia Zaman 2, Luis Avila 4, Parag Mehta 4 and Probal Banerjee 1,2,5, *  \nAcademic Editor: Aleksandra Majchrzak-Celi ´nska  \nReceived: 20 May 2026  \nRevised: 10 July 2026  \nAccepted: 19 July 2026  \nPublished: 27 July 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Chemistry, The College of Staten Island (CUNY), Staten Island, NY 10314, USA; [shubhasmitamohapatra@gmail.com](shubhasmitamohapatra@gmail.com)  \n2 Doctoral Program in Biochemistry, The College of Staten Island (CUNY), New York, NY 10314, USA; [adrian.guerrero.cordova@gmail.com](adrian.guerrero.cordova@gmail.com) (A.G.); [takiazaman@gmail.com](takiazaman@gmail.com) (K.T.Z.)  \n3 Department of Radiology, Bernard and Irene Schwartz Center for Biomedical Imaging & Center for Advanced Imaging Innovation and Research and Preclinical Imaging, Division for Advanced Research Technologies, New York University Grossman School of Medicine, New York, NY 10016, USA; [neha.rahman@nyulangone.org](neha.rahman@nyulangone.org) (N.R.); [stefan.markovic@nyulangone.org](stefan.markovic@nyulangone.org) (S.M.);  \nlauren.o’[donnell@nyulangone.org](donnell@nyulangone.org) (L.O.); [youssef.zaimwadghiri@nyulangone.org](youssef.zaimwadghiri@nyulangone.org) (Y.Z.W.)  \n4 Aveta Biomics, Inc., 110 Great Road, Suite 302, Bedford, MA 01730, USA; [lavila@avetabiomics.com](lavila@avetabiomics.com) (L.A.); [pmehta@avetabiomics.com](pmehta@avetabiomics.com) (P.M.)  \n5 Center for Developmental Neuroscience, The College of Staten Island (CUNY), Staten Island, NY 10314, USA  \n* [Correspondence: probalbanerjee@yahoo.com](Correspondence: probalbanerjee@yahoo.com)  \nAbstract  \nAPG157DS is a multi-component investigational drug which is currently the subject of multiple cancer trials. It has shown promising efficacy in patients with head and neck cancer. We report its immuno-modulatory effect in a syngeneic mouse model of glioblastoma (GBM). Long-term treatment with APG157DS led to durable tumor remission in 50% of mice, while all vehicle-treated mice reached humane endpoints within 42 days. Mechanistically, the drug induced selective repolarization of tumor-associated macrophages (TAMs) from an immunosuppressive Arg1high /iNOSlow phenotype to a tumoricidal Arg1low /iNOShigh state, accompanied by increased intratumoral recruitment of activated (NKp46+) natural killer cells and CD8+ cytotoxic T-cells. APG157DS also suppressed vascular endothelial growth factor (VEGF) and Hypoxia-inducible factor 1-alpha (HIF-1α) expression in tumors, further impairing tumor growth. Notably, APG157DS did not elicit off-target macrophage activation in peripheral tissues such as the spleen, highlighting its selective immune targeting. These findings provide a mechanistic rationale for further clinical development of APG157DS in GBM and potentially other immune-evasive cancers.  \nKeywords: APG157DS; curcumin; glioblastoma; tumor-associated microglia and macrophages (TAMs); M2/M1; Arg1/iNOS  \n1. Introduction  \nAPG157DS is a novel, orally administered immuno-oncology drug [1] . It is being investigated as a single agent in head and neck cancer [2,3] and in combination with anti-VEGF drug bevacizumab for recurrent glioma. The drug contains a key zinflavonoid (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, also known as diferuloylmethane (DFM) . The anticancer activity of DFM has been reported in many publications, but the earlier generations of drugs with DFM did not yield convincing results in  \nclinical trials. Meanwhile, findings in a syngeneic mouse model","cbCaitotIwK9xsut","https://ap.wps.com/l/cbCaitotIwK9xsut","pdf",15719557,17,"English","# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"What effect did long-term APG157DS treatment have in the syngeneic glioblastoma model?\",\"answer\":\"Long-term APG157DS treatment produced durable tumor remission in 50% of mice, while all vehicle-treated mice reached humane endpoints within 42 days.\"},{\"question\":\"How does APG157DS mechanistically change tumor-associated macrophages?\",\"answer\":\"APG157DS selectively repolarizes tumor-associated macrophages from an Arg1high/iNOSlow immunosuppressive phenotype to a tumoricidal Arg1low/iNOShigh state.\"},{\"question\":\"What evidence indicates APG157DS has selective immune targeting?\",\"answer\":\"APG157DS did not elicit off-target macrophage activation in peripheral tissues such as the spleen, indicating selective immune targeting.\"}]","First-in-Class Immuno-Oncology Drug APG157DS Repolarizes Innate Immune Cells and Induces Durable Remission in a Syngeneic Glioblastoma Model | PDF",1790112432,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/374645275c577c405124020a04fdaa47.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0d81df4a25c5b7ee901ecf0435e3ff7.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6911de4e5eef112b3d48d80820367a47.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09c3b0fb09ba5882c2a672b660ba3365.webp",980,1385]